VintaBio delivers customized process development and GMP manufacturing services for cell and gene therapy. The company's development and manufacturing team has over a century of experience in the cell and gene therapy space and has been involved in the development of some of the most advanced therapies on the market. Situated in the historic Navy Yards of Philadelphia, an epicenter of cell and gene therapy innovation, VintaBio specializes in developing and manufacturing consistent, high-quality viral vectors, addressing an underserved area of CGT development. Co-founded by Junwei Sun and Dr. Shangzhen Zhou, who were pivotal in the development of the AAV vectors behind the first two FDA-approved gene therapies and the lentiviral vector for the first FDA-approved cell therapy, the company has raised a substantial $64 million in venture funding. This funding has facilitated the development of a new 22,500 square foot facility in Philadelphia, specifically designed for efficient cell and gene therapy manufacturing. The latest $64.00M Venture Round investment on 11th April 2023 was led by Decheng Capital.
General Information
BounceWatch is an independent company data service, not affiliated with VintaBio. To contact VintaBio, visit vintabio.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does VintaBio compare?
A PDF of VintaBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting VintaBio soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is VintaBio on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
United States Market
Biotechnology
About VintaBio
Business keywords: cell therapy, gene therapy, process development, GMP manufacturing, viral vectors, AAV vectors, lentiviral vectors, venture funding, Philadelphia, innovation, FDA-approved therapies, facility development, team expertise, Navy Yards
Funding Rounds & Investors (1)
View AllVintaBio Alternatives & Competitors
View All AlternativesEnd-to-end ATMP CDMO/CRO that provides innovative offerings at each stage for biopharmaceutical prod...
Our mission is to leverage the power of gene and cell therapy to reduce human suffering from serious...
GMP Contract Manufacturing Organization for Biological Therapies and Vaccines for Human Clinical Tri...
FAQ About VintaBio
Source: BounceWatch company record for VintaBio, https://www.bouncewatch.com/company/vintabio, updated 25 November 2024. When citing, please name BounceWatch and link this page.